Recent advances in understanding and managing chordomas.

Area of Science:

• Oncology
• Orthopedics
• Genetics

Background:

• Chordomas are rare primary bone tumors originating from embryonic notochord remnants.
• These tumors are characterized by slow growth, local aggressiveness, and destructive potential, primarily affecting the axial skeleton.
• Genetic mutations play a role in chordoma pathogenesis, posing treatment challenges due to insidious progression and high recurrence rates.

Purpose of the Study:

• To review the current understanding of chordoma pathogenesis, clinical presentation, and treatment strategies.
• To highlight the challenges in managing chordomas due to their aggressive nature and poor response to conventional therapies.
• To discuss recent advancements in targeted chemotherapy and radiation therapy for improved chordoma management.

Main Methods:

• Literature review of genetic studies, clinical presentations, and treatment outcomes for chordomas.
• Analysis of the efficacy of radical resection as the primary treatment modality.
• Evaluation of recent advances in targeted chemotherapy and focused particle beam radiation.

Main Results:

• Chordomas are locally aggressive tumors with a high propensity for recurrence.
• Conventional chemotherapy and radiation show limited efficacy in treating chordomas.
• Radical surgical resection remains the cornerstone of treatment.
• Emerging targeted therapies and particle beam radiation show promise in improving outcomes.

Conclusions:

• Chordomas present significant management challenges due to their aggressive behavior and resistance to conventional treatments.
• Radical resection is currently the most effective treatment, but recurrence remains a concern.
• Recent advancements in targeted chemotherapy and focused particle beam radiation offer improved therapeutic options and prognosis for chordoma patients.